Sanofi has opened a new UK Headquarters, based at Thames Valley Park in Reading, Berkshire.
The company welcomed Matt Hancock, secretary of state for health and social care, to open the “state of the art” facility, along side Paul Hudson, chief executive officer of Sanofi and Hugo Fry, UK’s managing director.
The new 70,000 square ft. office facility marks a £37 million investment to Reading and will be the new base for 500 of the 1,200 employees in the UK.
“We are delighted to unveil our new headquarters and it has been an honour to welcome the Rt Hon Matt Hancock, secretary of state for health and social care, to today’s event,” says Hugo Fry, managing director at Sanofi in the UK.
He continued, “Thames Valley Park is well located and connected, but also home to global technology leaders and one of the best places for life sciences in the world. Just as delivering the best outcomes for the one million UK patients we support every month is important to us, we paid particular attention to designing a space that promotes the health and wellbeing of our employees.”
The company revealed that it is actively seeking to recruit at least 50 new roles in the coming months, in addition to ten graduate students via its new Aspiring Leaders programme.
By Anna Smith
Source: Pharma Times
The deal will enhance Merck’s expertise in developing and manufacturing mRNA for its customers for use in vaccines, treatments and diagnostics applicable in Covid-19 and various other diseases.
It’s the first significant visual redesign for Pfizer in 70 years since the company began using the blue oval background. The tagline outlining Pfizer’s purpose, “Breakthroughs that change patients’ lives,” remains the same.
The massive growth of gene therapy research and development over the last few years has boosted demand for viral vectors, the engineered viruses used to deliver therapeutic genes into patients’ bodies. Tokyo-based Fujifilm Diosynth Biotechnologies is stepping up to meet that demand.
